In sheep, central leptin infusion reduces food intake and increases energy expenditure in adipose tissue and skeletal muscle. The mechanisms for these peripheral effects of central leptin in sheep are not known but, on the basis of rodent studies, may involve AMPK. In mice, central leptin acutely increases both skeletal muscle AMPK activation and glucose uptake. Thus, to investigate whether these effects exist in higher-order mammals, ovariectomized Corriedale ewes (n ϭ 4 per group) received a continuous lateral ventricular infusion (60 l/h) of either leptin (50 g/h) or artificial cerebrospinal fluid (aCSF; CON) for 8 days. Tritiated glucose (3-3 H-glucose) was infused intravenously for calculation of whole body glucose turnover during both acute (6 h) and chronic (7-8 days) leptin/aCSF infusion. Muscle biopsies were also obtained. Leptin infusion reduced (P Ͻ 0.05) food intake and body weight, and it also increased plasma epinephrine concentration at 6 h and 7 days, suggesting increased sympathetic nerve activity. Despite this, and in contrast to rodent studies, central leptin infusion did not increase skeletal muscle AMPK␣ Thr 172 phosphorylation or ACC Ser 221 phosphorylation. Surprisingly, the glucose rate of appearance (glucose Ra) and rate of disappearance (glucose Rd) were reduced by both acute and chronic leptin infusion. Direct infusion of the AMPK activator 5-aminoimidazole-4-carboxyamide-ribonucleoside (AICAR) into the femoral artery increased skeletal muscle AMPK phosphorylation. In conclusion, although central leptin infusion in sheep caused the predicted reduction in food intake and increases plasma epinephrine concentration, it had no effect on AMPK activation in skeletal muscle and actually reduced glucose disposal. This suggests that there are species differences in the peripheral responses to central leptin infusion. glucose turnover; AICAR TYPE 2 DIABETES AND OBESITY are characterized by impaired glucose (68) and fat (46) metabolism in peripheral tissues, especially skeletal muscle. It has been proposed that inactivity of the energy-sensing enzyme AMPK, may play an important role in the development of these disorders (16,17,67). Acute pharmacological activation of AMPK by 5-aminoimidazole-4-carboxyamide-ribonucleoside (AICAR) increases glucose uptake (20,32,40) and fat oxidation (40, 43) in skeletal muscle.Administration of AICAR on a daily basis leads to favorable alterations in cellular bioenergetics (66) that can prevent diabetes in obese Zucker rats (50).Physiologically, AMPK is activated during exercise by an energy deficit in the cell via an increase in the AMP:ATP ratio (19). However, AMPK can also be activated in skeletal muscle by a number of other signals, including upstream AMPK kinase(s) (19), metformin (44), and in rodent skeletal muscle, by the adipocyte-derived hormone, leptin (43). Blood leptin levels are generally proportional to adipose tissue mass (15,35), and whether it is administered centrally or peripherally, leptin reduces food intake (41, 57) and increases energy expe...